- Home
- ABUS vs BRSP Comparison
ABUS vs BRSP Comparison
Compare ABUS & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABUS | BRSP |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.5M | 726.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ABUS | BRSP |
|---|---|---|
| Price | $4.84 | $5.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.4M | 812.3K |
| Earning Date | 11-13-2025 | 02-17-2026 |
| Dividend Yield | N/A | ★ 10.96% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,606,000.00 | ★ $330,894,000.00 |
| Revenue This Year | $125.30 | N/A |
| Revenue Next Year | N/A | $4.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 116.64 | N/A |
| 52 Week Low | $2.71 | $4.16 |
| 52 Week High | $5.10 | $6.32 |
Technical Indicators
Market Signals| Indicator | ABUS | BRSP |
|---|---|---|
| Relative Strength Index (RSI) | 57.71 | 50.62 |
| Support Level | $4.65 | $5.66 |
| Resistance Level | $5.05 | $5.94 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 67.46 | 48.79 |
Price Performance
Historical ComparisonAbout ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.